Association of pessimism with cardiovascular events and all-cause mortality

Chayakrit Krittanawong, Neil Sagar Maitra, Muzamil Khawaja, Zhen Wang, Sonya Fogg, Liron Rozenkrantz, Salim S. Virani, Morris Levin, Eric A. Storch, Philippe N. Tobler, Dennis S. Charney, Glenn N. Levine

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Poor psychological health is associated with Takotsubo cardiomyopathy, cardiac syndrome X, coronary microcirculatory dysfunction, peripheral artery disease, or spontaneous coronary artery dissection. Data regarding pessimism, cardiovascular disease (CVD) events and mortality and all-cause mortality remained inconclusive. This systematic review and meta-analysis aim to provide an overview of the association between pessimism, CVD outcomes and mortality. A systematic search of electronic databases was conducted from inception through July 2022 for studies evaluating pessimism and adverse outcomes. A total of 17 studies published between 1966 and July 2022 met our inclusion criteria, for a total of 232,533 individuals. Pooled hazard ratios were calculated in random-effects meta-analyses. Based on pooled analysis of adjusted HRs, pessimism was associated with adjusted HR of 1.13 (95% CI 1.07–1.19) for all-cause mortality with minimal heterogeneity (I2 = 28.5%). Based on pooled analysis of adjusted HRs, pessimism was associated with adjusted HR of 1.30 (95% CI 0.43–3.95) for CHD mortality, adjusted HR of 1.41 (95% CI 1.05–1.91) for CVD mortality, and adjusted HR of 1.43 (95% CI 0.64–3.16) for stroke. In conclusion, pessimism seems to be significantly associated with a higher risk for and poorer outcomes from CVD events than optimistic styles. There are genetic and other bases for these life approaches, but behavioral, cognitive and meditative interventions can modify patients' level of pessimism, hopefully leading to better medical outcomes. Testing this theory would yield highly useful and practical data for clinical care.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalProgress in Cardiovascular Diseases
Volume76
Early online date30 Nov 2022
DOIs
StatePublished - 1 Jan 2023

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Inc.

Funding

Dr. Krittanawong discloses the following relationships – Member of the American College of Cardiology Solution Set Oversight Committee, the American Heart Association Committee of the Council on Genomic and Precision Medicine, the American College of Cardiology/American Heart Association (ACC/AHA) Joint Committee on Clinical Data Standards, and the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Performance Measures, The Lancet Digital Health (Advisory Board), European Heart Journal Digital Health (Editorial board), Journal of the American Heart Association (Editorial board), JACC: Asia (Section Editor), The Journal of Scientific Innovation in Medicine (Associate Editor), and Frontiers in Cardiovascular Medicine (Associate Editor). Dr. Storch discloses the following relationships: consultant for Biohaven Pharmaceuticals; Book royalties from Elsevier, Springer, American Psychological Association, Wiley, Oxford, Kingsley, and Guilford; Research support from NIH, IOCDF, Ream Foundation, and Texas Higher Education Coordinating Board. Dr. Charney is named as co-inventor on patents filed by the Icahn School of Medicine at Mount Sinai (ISMMS) relating to the treatment for treatment-resistant depression, suicidal ideation and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), Dr. Charney is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, Dr. Charney, will be entitled to additional payments, beyond those already received, under the license agreement. Dr. Charney is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, Dr. Charney has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. Dr. Charney is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered Neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. Dr. Charney is a named co-inventor on a patent application in the US, and several issued patents outside the US filed by the ISMMS related to the use of ketamine for the treatment of post-traumatic stress disorder (PTSD). This intellectual property has not been licensed. All other authors have no disclosure.

FundersFunder number
American College of Cardiology/American Heart Association
Biohaven Pharmaceuticals
ISMMS Faculty Handbook
Lancet Digital Health
National Institutes of Health
American Heart Association
Texas Higher Education Coordinating Board
American Psychological Association
International OCD Foundation
Icahn School of Medicine at Mount Sinai
American Chemistry Council
REAM Foundation

    Keywords

    • All-cause mortality
    • Cardiovascular disease
    • Meta-analysis
    • Pessimism
    • Systematic review

    Fingerprint

    Dive into the research topics of 'Association of pessimism with cardiovascular events and all-cause mortality'. Together they form a unique fingerprint.

    Cite this